Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals

Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals

Understanding the magnitude of responses to vaccination during the ongoing SARS-CoV-2 pandemic is essential for ultimate mitigation of the disease. Here, we describe a cohort of 102 subjects (70 COVID-19-naïve, 32 COVID-19-experienced) who received two doses of one of the mRNA vaccines (BNT162b2 (Pf...

Full description

Bibliographic Details
Main Authors:	Susan L. Uprichard, Amornrat O’Brien, Monika Evdokimova, Cynthia L. Rowe, Cara Joyce, Matthew Hackbart, Yazmin E. Cruz-Pulido, Courtney A. Cohen, Michelle L. Rock, John M. Dye, Paul Kuehnert, Keersten M. Ricks, Marybeth Casper, Lori Linhart, Katrina Anderson, Laura Kirk, Jack A. Maggiore, Andrew S. Herbert, Nina M. Clark, Gail E. Reid, Susan C. Baker
Format:	Article
Language:	English
Published:	MDPI AG 2022-02-01
Series:	Viruses
Subjects:	SARS-CoV-2 COVID-19 vaccine response antibodies mRNA-1273 BNT162B2
Online Access:	https://www.mdpi.com/1999-4915/14/2/370

Similar Items

Is a single COVID-19 vaccine dose enough in convalescents ?
by: Daniele Focosi, et al.
Published: (2021-09-01)

BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
by: Anna Kaznadzey, et al.
Published: (2022-04-01)

IMUNOGENICIDADE DE UM PRIMEIRO REFORÇO COM BNT162B2 OU MRNA-1273 DE DOSE COMPLETA: UM ESTUDO RANDOMIZADO EM ADULTOS ≥75 ANOS (EU-COVAT-1) DO CONSÓRCIO VACCELERATE
by: Jon Salmanton-Garcia, et al.
Published: (2023-10-01)

Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers
by: Juan F. Delgado, et al.
Published: (2022-06-01)

Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
by: Daniele Focosi, et al.
Published: (2022-11-01)

Pre-graft vaccination or infection do not decrease COVID-19 infections in recipients of allogeneic stem cell transplantation vaccinated and/or protected by immunotherapy after transplant
by: Valentin Letailleur, et al.
Published: (2024-12-01)

Risk of herpes zoster following mRNA COVID-19 vaccine administration
by: Ana Florea, et al.
Published: (2023-12-01)

A multiprovincial retrospective analysis of the incidence of myocarditis or pericarditis after mRNA vaccination compared to the incidence after SARS-CoV-2 infection
by: Zaeema Naveed, et al.
Published: (2024-03-01)

Durability of Protection Post–Primary COVID-19 Vaccination in the United States
by: Amanda Zheutlin, et al.
Published: (2022-09-01)

Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States
by: Hagit Kopel, et al.
Published: (2024-09-01)

Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study
by: Soledad González, et al.
Published: (2022-09-01)

From trial to practice: incidence and severity of COVID-19 vaccine side effects in a medically at-risk and vaccine-hesitant community
by: Melinda C. Joyce, et al.
Published: (2022-12-01)

Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera
by: Thomas E. Hickey, et al.
Published: (2025-01-01)

Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees
by: Gabriele Anichini, et al.
Published: (2022-05-01)

The Dynamics of Changes in the Concentration of IgG against the S1 Subunit in Polish Healthcare Workers in the Period from 1 to 12 Months after Injection, Including Four COVID-19 Vaccines
by: Monika Skorupa, et al.
Published: (2022-03-01)

Peripheral Nervous System Adverse Events after the Administration of mRNA Vaccines: A Systematic Review and Meta-Analysis of Large-Scale Studies
by: Yu-Hsin Lai, et al.
Published: (2022-12-01)

Third vaccine boosters and anti‐S‐IgG levels: A comparison of homologous and heterologous responses and poor immunogenicity in hepatocellular carcinoma
by: Chih‐Wen Wang, et al.
Published: (2024-05-01)

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
by: Farah M. Shurrab, et al.
Published: (2022-01-01)

SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination
by: Kevin D. Dieckhaus, et al.
Published: (2023-02-01)

Safety and efficacy of RNA vaccines: State of the art
by: A. V. Blagov, et al.
Published: (2021-11-01)

Vaccine‐induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?
by: Julien Favresse, et al.
Published: (2024-08-01)

Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants
by: Nigam H. Padhiar, et al.
Published: (2022-05-01)

Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework
by: Sushma Kavikondala, et al.
Published: (2024-03-01)

A Response to: A Letter to the Editor Regarding ‘Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework’
by: Ekkehard Beck, et al.
Published: (2024-08-01)

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE
by: Sushma Kavikondala, et al.
Published: (2024-05-01)

COVID-19 Vaccination of Individuals with Down Syndrome—Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated
by: Anke Hüls, et al.
Published: (2022-03-01)

Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines
by: Cynthia M. Rohde, et al.
Published: (2023-02-01)

SARS-CoV-2 mRNA Vaccine Breakthrough Infections in Fully Vaccinated Healthcare Personnel: A Systematic Review
by: Caterina Ledda, et al.
Published: (2022-01-01)

Influence of the Single Nucleotide Polymorphisms rs12252 and rs34481144 in <i>IFITM3</i> on the Antibody Response after Vaccination against COVID-19
by: Ieva Čiučiulkaitė, et al.
Published: (2023-07-01)

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence
by: Daniele Focosi, et al.
Published: (2022-01-01)

Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV
by: Wang-Da Liu, et al.
Published: (2024-08-01)

Key Lessons from COVID-19: A Narrative Review Describing Qatar’s Multifactorial Approach in Executing a Vaccination Campaign
by: Soha Albayat, et al.
Published: (2023-05-01)

Acquired hemophilia A (AHA) due to anti‐SARS‐CoV‐2 vaccination: A systematic review
by: Fnu Amisha, et al.
Published: (2023-05-01)

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
by: Chiranjib Chakraborty, et al.
Published: (2021-07-01)

Protection against MIS-C outweighs the risk of myocarditis after Covid-19 vaccination in children
by: Marcello Mariani, et al.
Published: (2022-08-01)

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases
by: Catherine E. Raptis, et al.
Published: (2022-10-01)

Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)
by: Giulia Vivaldi, et al.
Published: (2022-11-01)

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
by: Hao Zhou, et al.
Published: (2021-08-01)

Sex Differences in Serious Adverse Events Reported Following Booster Doses of COVID-19 Vaccination in Thailand: A Countrywide Nested Unmatched Case-Control Study
by: Chawisar Janekrongtham, et al.
Published: (2023-11-01)

Positive aspects of the mRNA platform for SARS-CoV-2 vaccines
by: Khalid Hajissa, et al.
Published: (2021-08-01)